Details of the Drug Combination

General Information of Drug Combination (ID: DCJ34B6)

Drug Combination Name
ABIRATERONE Uracil mustard
Indication
Disease Entry Status REF
Melanoma Investigative [1]
Component Drugs ABIRATERONE   DM8V75C Uracil mustard   DMHL7OB
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SK-MEL-2
Zero Interaction Potency (ZIP) Score: 17.54
Bliss Independence Score: 17.7
Loewe Additivity Score: 0.21
LHighest Single Agent (HSA) Score: 15.14

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of Uracil mustard
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [3]
Chronic myelogenous leukaemia 2A20.0 Approved [4]
Polycythemia vera 2A20.4 Approved [4]
Small lymphocytic lymphoma 2A82.0 Approved [4]
Uracil mustard Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [6]
------------------------------------------------------------------------------------
Uracil mustard Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Increases ADR [7]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Increases ADR [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCA9LYN MOLT-4 Investigative [8]
Astrocytoma DCYTEU1 SNB-19 Investigative [8]
Chronic myelogenous leukemia DCV7CVY K-562 Investigative [8]
Clear cell renal cell carcinoma DC1BUQT 786-0 Investigative [8]
Clear cell renal cell carcinoma DC9I1OL CAKI-1 Investigative [8]
Glioma DCNK2AY SF-295 Investigative [8]
Plasma cell myeloma DC60KCI RPMI-8226 Investigative [8]
Renal cell carcinoma DCSMOYD UO-31 Investigative [8]
Breast adenocarcinoma DC3EVNE MDA-MB-468 Investigative [9]
Carcinoma DCAPZRN MCF7 Investigative [9]
Colon carcinoma DCF3SXR KM12 Investigative [9]
Adenocarcinoma DCRFAJW HCT-15 Investigative [1]
Adenocarcinoma DCPOZAB HCT116 Investigative [1]
High grade ovarian serous adenocarcinoma DC3IMSZ OVCAR-8 Investigative [1]
Lung adenocarcinoma DCI0YQB NCI-H522 Investigative [1]
Ovarian serous cystadenocarcinoma DCHRFDT SK-OV-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
4 Uracil mustard FDA Label
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165